{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:00:33Z","timestamp":1790103633766,"version":"4.0.1"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"38","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,18]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Creatinine-based estimated glomerular filtration rate (eGFRcr) may not fully capture mortality-related vulnerability in adults with dysglycemia. We examined whether cystatin C-based eGFR (eGFRcys) discordance and category reclassification were associated with mortality in 2 population-based cohorts analyzed separately. Adults with dysglycemia from National Health and Nutrition Examination Survey (NHANES) 1999 to 2002 and China Health and Retirement Longitudinal Study (CHARLS) 2011 were followed for mortality through 2019 and wave 4\/2018, respectively. eGFRdiff was defined as eGFRcys minus eGFRcr. Occult kidney dysfunction was defined as eGFRcr\u2005\u226560 and eGFRcys\u2005&lt;60\u2009mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      . Reclassification to a worse eGFR category was defined as assignment to a lower category by eGFRcys than by eGFRcr. The cohorts were analyzed separately using multivariable Cox models; NHANES analyses incorporated the cystatin C surplus-sample survey design. NHANES included 1531 participants and 981 deaths through 2019; CHARLS included 5231 participants and 579 deaths through 2018. Occult kidney dysfunction was present in 12.1% and 17.9%, respectively, and reclassification to a worse eGFR category occurred in 30.4% and 56.1%. In fully adjusted models, each 10\u2009mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      lower eGFRdiff was associated with all-cause mortality in NHANES (hazard ratio [HR], 1.24; 95% confidence interval [CI], 1.14\u20131.35) and CHARLS (HR, 1.15; 95% CI, 1.08\u20131.23). Occult kidney dysfunction was also associated with mortality in NHANES (HR, 1.58; 95% CI, 1.25\u20131.99) and CHARLS (HR, 1.27; 95% CI, 1.01\u20131.60). NHANES heart disease mortality showed concordant associations for eGFRdiff and occult kidney dysfunction. Some categorical CHARLS estimates were attenuated in sensitivity analyses, and direct comparisons indicated limited incremental information from discordance measures beyond eGFRcys alone. Cystatin C-based eGFR discordance was associated with mortality among adults with dysglycemia. It may identify higher-risk subgroups when eGFRcr appears preserved, although its incremental prognostic information beyond eGFRcys alone was limited.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050748","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:01:05Z","timestamp":1789750865000},"page":"e50748","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Cystatin C-based eGFR discordance and mortality risk in adults with dysglycemia"],"prefix":"10.1097","volume":"105","author":[{"given":"Xiaoyu","family":"Wei","sequence":"first","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, The First Medical Center, Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5054-8870","authenticated-orcid":false,"given":"Mingliang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, The First Medical Center, Chinese PLA General Hospital, Beijing, China"},{"name":"School of Medicine, Nankai University, Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260922","doi-asserted-by":"crossref","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045.","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"R2-20260922","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies.","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"R3-20260922","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1008862","article-title":"Diabetes mellitus, fasting glucose, and risk of cause-specific death.","volume":"364","author":"Rao Kondapally Seshasai","year":"2011","journal-title":"N Engl J Med"},{"key":"R4-20260922","doi-asserted-by":"crossref","first-page":"m2297","DOI":"10.1136\/bmj.m2297","article-title":"Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis.","volume":"370","author":"Cai","year":"2020","journal-title":"BMJ"},{"key":"R5-20260922","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jama.2016.10924","article-title":"Clinical manifestations of kidney disease among US adults with diabetes, 1988\u20132014.","volume":"316","author":"Afkarian","year":"2016","journal-title":"JAMA"},{"key":"R6-20260922","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis.","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"issue":"Supplement_1","key":"R7-20260922","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.2337\/dc26-S010","article-title":"10. Cardiovascular disease and risk management: standards of care in diabetes-2026.","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"issue":"Supplement_1","key":"R8-20260922","doi-asserted-by":"crossref","first-page":"S246","DOI":"10.2337\/dc26-S011","article-title":"11. Chronic kidney disease and risk management: standards of care in diabetes-2026.","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"key":"R9-20260922","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).","volume":"45","author":"de Boer","year":"2022","journal-title":"Diabetes Care"},{"key":"R10-20260922","doi-asserted-by":"crossref","first-page":"381","DOI":"10.7326\/M22-2904","article-title":"Diabetes management in chronic kidney disease: synopsis of the KDIGO 2022 clinical practice guideline update.","volume":"176","author":"Navaneethan","year":"2023","journal-title":"Ann Intern Med"},{"key":"R11-20260922","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.kint.2023.10.016","article-title":"Executive summary of the KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease: known knowns and known unknowns.","volume":"105","author":"Levin","year":"2024","journal-title":"Kidney Int"},{"key":"R12-20260922","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.","volume":"375","author":"Matsushita","year":"2010","journal-title":"Lancet"},{"key":"R13-20260922","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate.","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"R14-20260922","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C.","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med"},{"key":"R15-20260922","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race.","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"R16-20260922","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/ki.2008.638","article-title":"Factors other than glomerular filtration rate affect serum cystatin C levels.","volume":"75","author":"Stevens","year":"2009","journal-title":"Kidney Int"},{"key":"R17-20260922","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1053\/j.ajkd.2016.07.021","article-title":"Non-GFR determinants of low-molecular-weight serum protein filtration markers in CKD.","volume":"68","author":"Liu","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"R18-20260922","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.34067\/KID.0003202022","article-title":"Advantages, limitations, and clinical considerations in using cystatin C to estimate GFR.","volume":"3","author":"Chen","year":"2022","journal-title":"Kidney360"},{"key":"R19-20260922","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1214234","article-title":"Cystatin C versus creatinine in determining risk based on kidney function.","volume":"369","author":"Shlipak","year":"2013","journal-title":"N Engl J Med"},{"key":"R20-20260922","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1001\/jama.2011.468","article-title":"Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality.","volume":"305","author":"Peralta","year":"2011","journal-title":"JAMA"},{"key":"R21-20260922","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1681\/ASN.2010050483","article-title":"Cystatin C identifies chronic kidney disease patients at higher risk for complications.","volume":"22","author":"Peralta","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"R22-20260922","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1161\/CIRCULATIONAHA.106.644286","article-title":"Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the heart and soul study.","volume":"115","author":"Ix","year":"2007","journal-title":"Circulation"},{"key":"R23-20260922","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1161\/CIRCHEARTFAILURE.112.966960","article-title":"Cystatin C identifies patients with stable chronic heart failure at increased risk for adverse cardiovascular events.","volume":"5","author":"Dupont","year":"2012","journal-title":"Circ Heart Fail"},{"key":"R24-20260922","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1001\/jama.2025.17578","article-title":"Discordance in creatinine- and cystatin C-based eGFR and clinical outcomes: a meta-analysis.","volume":"334","author":"Estrella","year":"2025","journal-title":"JAMA"},{"key":"R25-20260922","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1053\/j.ajkd.2025.03.018","article-title":"Complex etiologies of the discordance between cystatin C- and creatinine-based estimated GFR and its adverse associations: findings from the CRIC study.","volume":"86","author":"McCoy","year":"2025","journal-title":"Am J Kidney Dis"},{"key":"R26-20260922","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1093\/ckj\/sfac070","article-title":"Cystatin C-based estimated GFR performs best in identifying individuals with poorer survival in an unselected Chinese population: results from the China Health and Retirement Longitudinal Study (CHARLS).","volume":"15","author":"Zhu","year":"2022","journal-title":"Clin Kidney J"},{"key":"R27-20260922","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/ije\/dys203","article-title":"Cohort profile: the China Health and Retirement Longitudinal Study (CHARLS).","volume":"43","author":"Zhao","year":"2014","journal-title":"Int J Epidemiol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050748","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:04:13Z","timestamp":1790100253000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050748"}},"subtitle":["Parallel cohort analyses of NHANES and CHARLS"],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":27,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050748","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"assertion":[{"value":"2026-06-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}